Compare CPIX & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPIX | SCNX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 16.2M |
| IPO Year | 2007 | 2019 |
| Metric | CPIX | SCNX |
|---|---|---|
| Price | $8.20 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 50.8K | ★ 303.8K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,010,949.00 | $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.75 | ★ 30.72 |
| 52 Week Low | $1.85 | $0.24 |
| 52 Week High | $9.28 | $2.60 |
| Indicator | CPIX | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 39.55 |
| Support Level | $7.34 | $0.30 |
| Resistance Level | $8.27 | $0.43 |
| Average True Range (ATR) | 0.38 | 0.02 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 90.66 | 37.33 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.